Eads & Heald Wealth Management Has $870,000 Stock Position in The Clorox Company $CLX

Eads & Heald Wealth Management lowered its stake in The Clorox Company (NYSE:CLX) by 10.2% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 7,245 shares of the company’s stock after selling 824 shares during the period. Eads & Heald Wealth Management’s holdings in Clorox were worth $870,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of CLX. American National Bank & Trust raised its position in shares of Clorox by 69.5% in the 2nd quarter. American National Bank & Trust now owns 217 shares of the company’s stock valued at $26,000 after buying an additional 89 shares in the last quarter. Ransom Advisory Ltd bought a new position in Clorox in the first quarter valued at approximately $35,000. GW&K Investment Management LLC raised its position in Clorox by 239.1% during the first quarter. GW&K Investment Management LLC now owns 295 shares of the company’s stock valued at $43,000 after purchasing an additional 208 shares in the last quarter. Ameritas Advisory Services LLC bought a new stake in Clorox during the second quarter worth $48,000. Finally, Roble Belko & Company Inc boosted its holdings in shares of Clorox by 140.7% in the 1st quarter. Roble Belko & Company Inc now owns 361 shares of the company’s stock valued at $53,000 after purchasing an additional 211 shares in the last quarter. Institutional investors and hedge funds own 78.53% of the company’s stock.

Insiders Place Their Bets

In other Clorox news, COO Eric H. Reynolds sold 15,041 shares of the firm’s stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $123.78, for a total transaction of $1,861,774.98. Following the completion of the transaction, the chief operating officer owned 54,221 shares in the company, valued at approximately $6,711,475.38. This trade represents a 21.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.57% of the company’s stock.

Clorox Stock Performance

NYSE CLX opened at $123.30 on Monday. The company has a market capitalization of $15.08 billion, a price-to-earnings ratio of 18.91, a PEG ratio of 1.00 and a beta of 0.52. The company has a quick ratio of 0.57, a current ratio of 0.84 and a debt-to-equity ratio of 5.15. The Clorox Company has a twelve month low of $116.53 and a twelve month high of $171.37. The stock has a fifty day simple moving average of $122.81 and a 200 day simple moving average of $129.41.

Clorox (NYSE:CLX) last announced its earnings results on Thursday, July 31st. The company reported $2.87 EPS for the quarter, topping the consensus estimate of $2.24 by $0.63. Clorox had a return on equity of 377.86% and a net margin of 11.40%.The firm had revenue of $1.99 billion for the quarter, compared to the consensus estimate of $1.94 billion. During the same period in the previous year, the business earned $1.82 EPS. The business’s quarterly revenue was up 4.5% compared to the same quarter last year. Clorox has set its FY 2026 guidance at 5.950-6.30 EPS. Sell-side analysts expect that The Clorox Company will post 7.15 EPS for the current year.

Clorox Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, November 6th. Shareholders of record on Wednesday, October 22nd will be given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 4.0%. The ex-dividend date of this dividend is Wednesday, October 22nd. Clorox’s dividend payout ratio is currently 76.07%.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on CLX. Citigroup reissued a “neutral” rating and set a $135.00 price target (down previously from $140.00) on shares of Clorox in a report on Tuesday, July 15th. Jefferies Financial Group lowered their target price on Clorox from $167.00 to $145.00 and set a “buy” rating for the company in a research note on Thursday, June 26th. Zacks Research raised shares of Clorox from a “strong sell” rating to a “hold” rating in a report on Monday, September 29th. The Goldman Sachs Group decreased their price target on shares of Clorox from $115.00 to $110.00 and set a “sell” rating on the stock in a report on Wednesday, October 1st. Finally, TD Cowen dropped their price objective on shares of Clorox from $120.00 to $117.00 and set a “hold” rating for the company in a research note on Wednesday, October 1st. One investment analyst has rated the stock with a Buy rating, ten have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Clorox presently has an average rating of “Reduce” and a consensus price target of $134.08.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.